# The Liquidity Challenge of Real-World Medical Assets Beyond data, another critical bottleneck lies in the illiquidity of **Real-World Medical Assets (RWA)**. These assets include, but are not limited to: * Intellectual Property: Such as drug patents, biotechnology patents, medical method patents, etc. * Commercialization Right: Such as medical equipment manufacturing rights, distribution licenses, operation rights, etc. * R\&D Data and Outcome: Such as clinical trial datasets, research project outputs, innovation validation data, etc. * Comprehensive Innovation Assets: Such as integrated healthcare solution packages combining intellectual property and data. Such assets are the backbone of biomedical progress, yet remain largely untapped due to complex valuation, lengthy transaction cycles, and limited trust mechanisms. Early-stage biotech projects and research outputs, often unstandardized and illiquid, struggle to attract sustainable funding — constraining innovation efficiency across the healthcare sector. --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://dna-6.gitbook.io/docs.dna.living/background-and-problem-statement/the-liquidity-challenge-of-real-world-medical-assets.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.